Thrombolysis With Tenecteplase for Minor Disabling Stroke

Did outcomes following intravenous tenecteplase for minor ischemic stroke vary based on the presence of disabling deficits?In this secondary analysis of the TEMPO-2 randomized clinical trial including 884 patients with minor ischemic stroke and proven intracranial occlusion, both patients with and without disabling deficits defined according to US National Institutes of Health Stroke Scale (NIHSS)–based criteria showed a neutral treatment effect from intravenous tenecteplase, with no significant effect modification.Current definitions of disabling stroke did not modify the neutral treatment effect of intravenous tenecteplase in patients with minor stroke and intracranial occlusion.

Corresponding Author: Shelagh B. Coutts, MD, Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, 1403 29th St NW, Calgary, AB T2N 2T9, Canada (scoutts@ucalgary.ca).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.